Cara Therapeutics ROCE 2024

Cara Therapeutics Aktienanalyse

What does Cara Therapeutics do?

Cara Therapeutics Inc. is a US pharmaceutical company based in Stamford, Connecticut, specializing in the development of novel therapies for the treatment of pain conditions. The company was founded in 2004 by Derek Chalmers and Eric Carter and has been publicly traded on the NASDAQ since its IPO in 2014. Cara Therapeutics Inc.'s history is closely linked to the discovery of adenosine A2A receptor modulation. In recent years, the company has successfully utilized this class of compounds in innovative ways to develop novel pain treatment solutions. The company also has a close collaboration with Yale University and other leading research institutions in the field of neurology and pain research. Cara Therapeutics Inc.'s business model is based on the development and commercialization of new pain therapies, particularly based on Cara - a synthetic adenosine A2A receptor antagonist. The medications developed by Cara Therapeutics Inc. are designed to provide effective pain relief to patients without the strong side effects of traditional pain medications such as opioids. Cara Therapeutics Inc. is divided into several divisions that encompass different areas of the company. These include research and development, production, sales and marketing, as well as the supply chain. The research and development division of Cara Therapeutics Inc. works closely with leading research institutions and scientists to continuously develop new treatment options. The focus is always on the needs of patients and healthcare providers, with an emphasis on advancing treatment options with Cara and other new compounds. The production facilities of Cara Therapeutics Inc. are specialized in the production of Cara-based therapies and aim to ensure high quality and patient access. The company works closely with various partners domestically and internationally to ensure global patient access. The sales and marketing division of Cara Therapeutics Inc. is focused on placing the company's products on the market and communicating the benefits of the offered therapies to patients. The company relies on a global network of distribution partners and close collaboration with healthcare professionals. An important focus of the company is the supply chain - ensuring continuous patient access to necessary medications as well as ensuring compatibility and traceability of treatment options. Some of the most well-known and important products of Cara Therapeutics Inc. include Korsuva, a pain medication developed for the treatment of pruritus in patients with chronic kidney disease on hemodialysis, as well as a wide range of other pain therapies. Overall, Cara Therapeutics Inc. is an innovative company specializing in the treatment of pain conditions and is at the forefront of pain therapy research and development. The company places special emphasis on ensuring that their pain therapies are as effective and safe as possible in order to provide patients with effective pain relief. Cara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Cara Therapeutics's Return on Capital Employed (ROCE)

Cara Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Cara Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Cara Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Cara Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Cara Therapeutics Stock

What is the ROCE (Return on Capital Employed) of Cara Therapeutics this year?

The ROCE of Cara Therapeutics is -2.13 undefined this year.

How has the ROCE (Return on Capital Employed) of Cara Therapeutics developed compared to the previous year?

The ROCE of Cara Therapeutics has increased by 286.02% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Cara Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Cara Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Cara Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Cara Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Cara Therapeutics impact the company?

An increase in the ROCE of Cara Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Cara Therapeutics affect the company?

A decrease in ROCE of Cara Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Cara Therapeutics?

Some factors that can affect Cara Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Cara Therapeutics so important for investors?

The ROCE of Cara Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Cara Therapeutics take to improve the ROCE?

To improve the ROCE, Cara Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Cara Therapeutics pay?

Over the past 12 months, Cara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Cara Therapeutics?

The current dividend yield of Cara Therapeutics is .

When does Cara Therapeutics pay dividends?

Cara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cara Therapeutics?

Cara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cara Therapeutics located?

Cara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cara Therapeutics from 6/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/16/2024.

When did Cara Therapeutics pay the last dividend?

The last dividend was paid out on 6/16/2024.

What was the dividend of Cara Therapeutics in the year 2023?

In the year 2023, Cara Therapeutics distributed 0 USD as dividends.

In which currency does Cara Therapeutics pay out the dividend?

The dividends of Cara Therapeutics are distributed in USD.